欧米先進的金融機関のオペレーショナルリスク管理高度化 : 管理高度化フレームワークの提示と欧米先進的金融機関から学ぶべきこと<論文>

Recently, foreign banks as well as Japanese banks are facing duplication issues related to operational risk management in terms of regulatory burdens. It is important to implement operational risk management in more proactive way rather than reactive one to win internationally intensified competition. Thus, this paper aims for proposing an effective and efficient operational risk management framework based on the practices of advanced foreign banks. This framework is consistent with the recent innovation from COSO to COSO/ERM and from Basel I to Basel Ⅱ. Inaddition, three points of practical advice are proposed to Japanese banks in their enhancing operational risk management based on best practices of advanced foreign banks.textapplication/pdfdepartmental bulletin pape

眼窩前頭⽪質における味覚ワーキングメモリや報酬予測の⽣成に関する神経メカニズム

電気通信大学博士（工学）2022doctoral thesi

Observation of a Resonancelike Structure in the π^+-Ψ' Mass Distribution in Exclusive B → Kπ^+-Ψ' Decays

A distinct peak is observed in the π^±Ψ'invariant mass distribution near 4.43 GeV in B→ Kπ^±Ψ' decays. A fit using a Breit-Wigner resonance shape yields a peak mass and width of M = 4433± 4(stat)± 2(syst) MeV and Γ= 45\begin+18\-13\end(stat)\begin+30\-13\end(syst)MeV.The product branching fraction is determined to be B(B^0→ K^∓Z^±(4430)→ π^±Ψ')= (4.1±1.0(stat)±1.4(syst))×10^{-5}, where Z^±(4430)is used to denote the observed structure. The statistical significance of the observed peak is 6.5σ. These results are obtained from a 605 fb^{-1} data sample that contains 657 ×10^6 B\bar{B} pairs collected near the Υ(4S) resonance with the Belle detector at the KEKB asymmetric energy e^+e^- collider.journal articl

Search for CP Violation in the Decay B0→D*±D∓

journal articl

Proportion of patients with virological failure by predominant anchor drug (rows), and tenofovir exposure (>50%, columns) during the past 3 months.

Solid line: not on statins or CVMs, broken line: on other CVMs, dotted line: on statins. Statin use was associated with a decreased probability of virological failure independently of the ART regimen used.</p

Sensitivity Analysis.

<p>Hazard Ratio (95% CI) for first VF after sustained viral suppression >6 months (n = 14,389 / 6,295 failures).</p

Current use of statins reduces risk of HIV rebound on suppressive HAART

<div><p>Background</p><p>Despite compelling evidence for activity against HIV-1 <i>in vitro</i>, a virologic effect of statins has not been shown in clinical studies. Given their short plasma half-lives, such an effect may be transient and only apparent during ongoing exposure.</p><p>Methods</p><p>We studied all HIV infected US-Veterans who started HAART 1995–2011, had a documented HIV viral load (VL) >1000 copies/mL, reached an undetectable VL on HAART, and had ≥1 follow-up VL within 13 months. We defined virologic failure (VF) as the first VL >1,000 copies/mL or the first of 2 consecutive VL >200 copies/mL. We built a time-updated drug exposure model for antiretrovirals (ARVs), statins, and other cardiovascular drugs (CVMs), investigating current use (yes/no), recent use (proportion of days used), and categorical use (ever/never). We used both multiply adjusted and inverse-probability-weighted (IPW) Cox models to explore the association between statin and CVM use and VF.</p><p>Results</p><p>19,324 veterans met inclusion criteria. Median follow-up was 13 months (IQR: 5–32 months); 63% experienced VF after a median time of 9 months (IQR 4–21 months). Almost 1/3 patients ever used statins but exposure comprised only 41% of follow-up time covered after initial prescription. Unadjusted, current statin use was associated with a hazard ratio (HR) for VF of 0.60 (CI: 0.56–0.65). This remained statistically significant after multivariate adjustment (MVA) for demographics, HIV and HAART parameters [HR 0.81 (CI: 0.75–0.88), p<0.001] and IPW (truncation <1%/>99%) HR: 0.83 (CI: 0.75–0.92), p<0.001]. No independent association was observed for other CVMs. The association between categorical-statin use and VF after MVA was much weaker: HR 0.94 (CI: 0.88–1.00, p = 0.04).</p><p>Conclusion</p><p>Current statin exposure was associated with reduced risk of VF in univariate, multivariate, and inverse-probability-weighted models. Our results highlight the importance of time-updated medication exposure models for observational studies.</p></div

Baseline Characteristics <i>at the time of First VL Suppression</i>.

<p>Baseline Characteristics <i>at the time of First VL Suppression</i>.</p

Main Analysis.

<p>Hazard Ratio (95% CI) of first VF (n = 19,324 / 10, 534 failures).</p

Cross-sectional Selection of Time-Updated Characteristics by Statin and CVM Use (all patients under observation).

<p>Cross-sectional Selection of Time-Updated Characteristics by Statin and CVM Use (all patients under observation).</p